CA
NZ
UK
AU
IND
US
Moleculin Biotech (NASDAQ: MBRX) completed a financing transaction that delivered approximately $9.3 million in gross proceeds. The company issued an aggregate of 12,376,667 shares of its common stock, each bearing a par value of $0.001 per share, together with warrants that allow the purchase …
The acquisition will result in Neptune Engineering Limited becoming a 100% wholly owned subsidiary of Nano Mobile Healthcare, Inc. expanding its presence in the marine engineering sector. This deal is a significant step for Nano Mobile Healthcare, Inc. as it looks to diversify its …
Obsidian Therapeutics has finalized its merger with Galera Therapeutics, achieving a significant capital influx of $350 million through the issuance of Series C Non-Voting Convertible Preferred Stock. This merger, effective August 3, enhances Obsidian's financial capacity and positions it strategically within the biotech sector …
Investors are closely watching healthcare stocks this week as Eli Lilly prepares for its earnings report, which is anticipated to significantly impact market sentiment. Along with Eli Lilly, other notable companies set to disclose results include Revolution Medicines, Krystal Biotech, Hinge Health, Twilio, and …
Lantern Pharma (NASDAQ: LTRN) announced the formation of Open‑Medicine AI, a newly incorporated company that will own and commercialize the firm’s multi‑agent artificial‑intelligence platform originally released as withZeta.ai. The spin‑off targets a drug‑discovery market expected to surpass $10 billion by 2030, a growth arena …
Harvard Apparatus Regenerative Technology (OTC: HRGN) obtained a $300,000 bridge loan on April 13, 2026, with a fixed 8% annual interest rate. The infusion comes as the company seeks to sustain its regenerative‑technology pipeline while investors watch a market‑cap of $18 million.
Rising healthcare benefit costs are limiting wage growth for employees, contributing to frustrations over meager pay raises. For the past two decades, healthcare expenses for employers have climbed dramatically, placing financial strain on compensation packages. Employers are now faced with the challenge of managing …
Inspire Medical Systems, Inc. reports Q2 EPS of $0.14, beating estimates, and announces a strategic growth plan to boost revenue, which may lead to increased investment in the company. This move could potentially drive growth and improve the company's financial performance.Key HighlightsQ2 EPS of …
The transaction promises immediate liquidity for investors while ushering the medical‑device CDMO into private ownership, a move that could reshape its strategic flexibility.
Shares have surged 45.3% year‑to‑date, signaling strong investor appetite despite the earnings miss.
Please wait processing your request...